Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today the advancement of their collaboration for the discovery, development and commercialization of a recombinant polyclonal antibody therapeutic, Sym006, that targets an undisclosed bacterial pathogen. The companies, who initiated the collaboration in December 2006, are moving the program into preclinical development. As a result, Symphogen will receive a milestone payment from Meiji under the terms of the agreement.

More: continued here

This entry was posted on Friday, December 5th, 2008 at 1:12 am and is filed under Immune System / Vaccines. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.